{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:58:37Z","timestamp":1782424717295,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jiph.2020.12.023","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T13:05:09Z","timestamp":1609247109000},"page":"331-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Risk management strategies and therapeutic modalities to tackle COVID-19\/SARS-CoV-2"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-4684","authenticated-orcid":false,"given":"Syed Muhammad Ali","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-3183","authenticated-orcid":false,"given":"Muhammad","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-2720","authenticated-orcid":false,"given":"Hafiz M.N.","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-1266","authenticated-orcid":false,"given":"Luigi Geo","family":"Marceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-9067","authenticated-orcid":false,"given":"Elena","family":"Bobescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2020.12.023_bib0005","first-page":"395","article-title":"The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak","volume":"368","author":"Chinazzi","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.22207\/JPAM.14.1.05","article-title":"2019-NCOV\/COVID-19-Approaches to viral vaccine development and preventive measures","volume":"14","author":"Bilal","year":"2020","journal-title":"J Pure Appl Microbiol"},{"issue":"2","key":"10.1016\/j.jiph.2020.12.023_bib0015","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.22207\/JPAM.14.2.40","article-title":"Predicting COVID-19 spread in Pakistan using the SIR model","volume":"14","author":"Shah","year":"2020","journal-title":"J Pure Appl Microbiol"},{"issue":"4","key":"10.1016\/j.jiph.2020.12.023_bib0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiph.2020.12.023_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.22207\/JPAM.14.SPL1.09","article-title":"Coronaviruses and COVID-19\u2013Complications and lessons learned for the future","volume":"14","author":"Bilal","year":"2020","journal-title":"J Pure Appl Microbiol"},{"issue":"7","key":"10.1016\/j.jiph.2020.12.023_bib0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.jiph.2020.12.023_bib0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.jiph.2020.12.023_bib0040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2020.12.023_bib0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2020.12.023_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/256294","article-title":"Angiotensin-Converting Enzyme 2 (ACE2) is a keymodulator of the renin angiotensin systemin health and disease","volume":"2012","author":"Tikellis","year":"2012","journal-title":"Int J Pept"},{"key":"10.1016\/j.jiph.2020.12.023_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.amjcard.2020.06.002","article-title":"Angiotensin converting enzyme 2 may mediate disease severity in COVID-19","volume":"130","author":"Gue","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jiph.2020.12.023_bib0065","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1073\/pnas.0809524106","article-title":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites","volume":"106","author":"Belouzard","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jiph.2020.12.023_bib0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.jiph.2020.12.023_bib0075","series-title":"Host immune response and immunobiology of human SARS-CoV-2 infection, in Coronavirus Disease 2019 (COVID-19)","first-page":"43","author":"Kumar","year":"2020"},{"key":"10.1016\/j.jiph.2020.12.023_bib0080","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.1128\/JVI.01464-10","article-title":"Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein","volume":"84","author":"Liu","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and Pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","article-title":"Heightened innate immune responses in the respiratory tract of COVID-19 patients","volume":"27","author":"Zhou","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jiph.2020.12.023_bib0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fmolb.2020.00196","article-title":"Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19","volume":"7","author":"Chatterjee","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.22207\/JPAM.14.1.03","article-title":"The emergence of novel-coronavirus and its replication cycle: an overview","volume":"14","author":"Iqbal","year":"2020","journal-title":"J Pure Appl Microbiol"},{"issue":"10223","key":"10.1016\/j.jiph.2020.12.023_bib0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.jiph.2020.12.023_bib0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jiph.2020.12.023_bib0120","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.22207\/JPAM.14.2.06","article-title":"A case report of pregnant lady having COVID-19 delivered via cesarean section in tertiary care hospital in Pakistan","volume":"14","author":"Tarar","year":"2020","journal-title":"J Pure Appl Microbiol"},{"issue":"6","key":"10.1016\/j.jiph.2020.12.023_bib0125","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","article-title":"Evidence for gastrointestinal infection of SARS-CoV-2","volume":"158","author":"Xiao","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jiph.2020.12.023_bib0130","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jiph.2020.12.023_bib0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.46234\/ccdcw2020.033","article-title":"Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19)","volume":"2","author":"Zhang","year":"2020","journal-title":"China CDC Weekly"},{"issue":"1\u20132","key":"10.1016\/j.jiph.2020.12.023_bib0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jviromet.2005.02.005","article-title":"Study on the resistance of severe acute respiratory syndrome-associated coronavirus","volume":"126","author":"Wang","year":"2005","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12560-008-9001-6","article-title":"Survival of coronaviruses in water and wastewater","volume":"1","author":"Gundy","year":"2009","journal-title":"Food Environ Virol"},{"issue":"7","key":"10.1016\/j.jiph.2020.12.023_bib0150","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.watres.2009.02.002","article-title":"Survival of surrogate coronaviruses in water","volume":"43","author":"Casanova","year":"2009","journal-title":"Water Res"},{"key":"10.1016\/j.jiph.2020.12.023_bib0155","first-page":"929","article-title":"Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents","volume":"382","author":"Kampf","year":"2020","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jiph.2020.12.023_bib0160","series-title":"Guidelines for drinking-water quality: first addendum to the fourth edition","author":"Organization, W.H","year":"2017"},{"key":"10.1016\/j.jiph.2020.12.023_bib0165","unstructured":"SARS-CoV-2 \u2212 water and sanitation. Adelaide: Water Research Australia; 2020 (http:\/\/www.waterra.com.au\/_r9544\/media\/system\/attrib\/file\/2199\/WaterRA_FS_Coronavirus_V10.pdf, accessed 3 March 2020)."},{"key":"10.1016\/j.jiph.2020.12.023_bib0170","series-title":"Case studies in chemical and environmental engineering","article-title":"Water matrices as potential source of SARS-CoV-2 transmission\u2013An overview from environmental perspective","author":"Bilal","year":"2020"},{"key":"10.1016\/j.jiph.2020.12.023_bib0175","series-title":"In: WHO\/Infection prevention and control [website]","article-title":"My 5 moments for hand hygiene","year":"2020"},{"issue":"6","key":"10.1016\/j.jiph.2020.12.023_bib0180","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/infdis\/jix046","article-title":"Virucidal activity of world health organization\u2013recommended formulations against enveloped viruses, including Zika, Ebola, and emerging coronaviruses","volume":"215","author":"Siddharta","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiph.2020.12.023_bib0185","series-title":"WHO guidelines on hand hygiene in health care settings","year":"2009"},{"issue":"2","key":"10.1016\/j.jiph.2020.12.023_bib0190","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.22207\/JPAM.14.2.01","article-title":"Strategic measures for food processing and manufacturing facilities to combat coronavirus pandemic (COVID-19)","volume":"14","author":"Shahbaz","year":"2020","journal-title":"J Pure Appl Microbiol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0195","doi-asserted-by":"crossref","first-page":"749","DOI":"10.22207\/JPAM.14.SPL1.12","article-title":"Food safety and COVID-19: precautionary measures to limit the spread of coronavirus at food service and retail sector","volume":"14","author":"Shahbaz","year":"2020","journal-title":"J Pure Appl Microbiol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0200","series-title":"Health aspects of plumbing","author":"Organization","year":"2006"},{"key":"10.1016\/j.jiph.2020.12.023_bib0205","series-title":"Guidelines on sanitation and health","author":"Organization","year":"2018"},{"issue":"17","key":"10.1016\/j.jiph.2020.12.023_bib0210","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa032867","article-title":"Evidence of airborne transmission of the severe acute respiratory syndrome virus","volume":"350","author":"Yu","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.12.023_bib0215","unstructured":"Regan H. How can the coronavirus spread through bathroom pipes? Experts are investigating in Hong Kong. CNN. 12 February 2020 (https:\/\/edition.cnn.com\/2020\/02\/12\/asia\/hong-kong-coronaviruspipes-intlhnk\/index.html)."},{"key":"10.1016\/j.jiph.2020.12.023_bib0220","series-title":"Sanitation safety planning: manual for safe use and disposal of wastewater greywater and excreta","author":"Organization","year":"2015"},{"key":"10.1016\/j.jiph.2020.12.023_bib0225","series-title":"How to put on and take off personal protective equipment (PPE)","author":"Organization","year":"2008"},{"key":"10.1016\/j.jiph.2020.12.023_bib0230","unstructured":"Control, C. f. D.; Prevention, Guideline for disinfection and sterilization in healthcare facilities, 2008. URL: https:\/\/www.cdc.gov\/infectioncontrol\/pdf\/guidelines\/disinfection-guidelines.pdf (19.12. 2017) 2008."},{"key":"10.1016\/j.jiph.2020.12.023_bib0235","series-title":"Best practices for environmental cleaning in health-care facilities in resource-limited settings","year":"2019"},{"key":"10.1016\/j.jiph.2020.12.023_bib0240","series-title":"Safe management of wastes from health-care activities: a summary","author":"Organization","year":"2017"},{"key":"10.1016\/j.jiph.2020.12.023_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the anti-viral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2020.12.023_bib0250","first-page":"1","article-title":"Increasing host cellular receptor\u2014angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection","author":"Wang","year":"2020","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.jiph.2020.12.023_bib0255","first-page":"469","article-title":"Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV","volume":"80","author":"Li","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2020.12.023_bib0260","unstructured":"Available at: https:\/\/clinicaltrials.gov\/ Last accessed on 07 Apr 2020."},{"key":"10.1016\/j.jiph.2020.12.023_bib0265","unstructured":"Available at: http:\/\/www.chictr.org.cn\/enindex.aspx Last accessed on 07 Apr 2020."},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0270","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-017-1393-y","article-title":"Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling","volume":"19","author":"Wu","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.jiph.2020.12.023_bib0275","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Ku\u017enik","year":"2011","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.jiph.2020.12.023_bib0280","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase\u2013DNA interaction","volume":"194","author":"An","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0285","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"Dijkmans","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jiph.2020.12.023_bib0295","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)"},{"key":"10.1016\/j.jiph.2020.12.023_bib0300","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jiph.2020.12.023_bib0305","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jiph.2020.12.023_bib0310","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiph.2020.12.023_bib0315","article-title":"Molecular modeling evaluation of the binding abilities of ritonavir and Lopinavir to Wuhan pneumonia coronavirus proteases","author":"Lin","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jiph.2020.12.023_bib0320","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jiph.2020.12.023_bib0325","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jiph.2020.12.023_bib0330","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jmii.2020.03.032","article-title":"Lopinavir\/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan","volume":"53","author":"Cheng","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"7594","key":"10.1016\/j.jiph.2020.12.023_bib0335","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2020.12.023_bib0340","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci Rep"},{"issue":"396","key":"10.1016\/j.jiph.2020.12.023_bib0345","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum anti-viral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jiph.2020.12.023_bib0350","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the anti-viral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.jiph.2020.12.023_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","author":"Al-Tawfiq","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.jiph.2020.12.023_bib0360","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jiph.2020.12.023_bib0365","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jiph.2020.12.023_bib0370","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0375","first-page":"9","article-title":"Current and future anti-virals medications to treat influenza: mechanisms of action","volume":"3","author":"Ramirez","year":"2019","journal-title":"Univ Louisville J Respir Infect"},{"issue":"6","key":"10.1016\/j.jiph.2020.12.023_bib0380","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jac\/dkr136","article-title":"Ribavirin for patients with Crimean\u2013congo haemorrhagic fever: a systematic review and meta-analysis","volume":"66","author":"Ascioglu","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0385","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.jiph.2020.12.023_bib0395","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","article-title":"Ribavirin and interferon-\u03b2 synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines","volume":"326","author":"Morgenstern","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jiph.2020.12.023_bib0400","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antiviral Res"},{"issue":"8","key":"10.1016\/j.jiph.2020.12.023_bib0405","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00705-007-0974-5","article-title":"Anti-viral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo","volume":"152","author":"Shi","year":"2007","journal-title":"Arch Virol"},{"key":"10.1016\/j.jiph.2020.12.023_bib0410","article-title":"Favipiravir versus Arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.jiph.2020.12.023_bib0415","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2020.12.023_bib0420","article-title":"An exploratory randomized, controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI)","author":"Li","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0425","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jiph.2020.12.023_bib0430","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2020.12.023_bib0435","series-title":"In Cytokine storm and sepsis disease pathogenesis","first-page":"517","author":"Chousterman","year":"2017"},{"issue":"5","key":"10.1016\/j.jiph.2020.12.023_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2020.12.023_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11684-019-0733-5","article-title":"Coronavirus disease 2019 (COVID-19): a clinical update","author":"Zhou","year":"2020","journal-title":"Front Med"},{"issue":"20","key":"10.1016\/j.jiph.2020.12.023_bib0450","first-page":"10970","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"issue":"1","key":"10.1016\/j.jiph.2020.12.023_bib0455","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon\u2010like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jiph.2020.12.023_bib0460","article-title":"Potent anti-viral activities of type I interferons to SARS-CoV-2 infection","author":"Mantlo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jiph.2020.12.023_bib0465","article-title":"SARS-CoV-2 sensitive to type I interferon pretreatment","author":"Lokugamage","year":"2020","journal-title":"BioRxiv"},{"issue":"7","key":"10.1016\/j.jiph.2020.12.023_bib0470","doi-asserted-by":"crossref","first-page":"497","DOI":"10.21037\/atm.2020.03.157","article-title":"Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm","volume":"8","author":"Lippi","year":"2020","journal-title":"Ann Transl Med"},{"issue":"10223","key":"10.1016\/j.jiph.2020.12.023_bib0475","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jiph.2020.12.023_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105967","article-title":"Baricitinib-a januase kinase inhibitor-not an ideal option for management of COVID 19","author":"Praveen","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2020.12.023_bib0485","article-title":"Traditional Chinese medicine for COVID-19 treatment","volume":"155","author":"Ren","year":"2020","journal-title":"Pharmacol Res"},{"issue":"14","key":"10.1016\/j.jiph.2020.12.023_bib0490","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.jiph.2020.12.023_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 vaccine: a comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res"},{"issue":"10249","key":"10.1016\/j.jiph.2020.12.023_bib0500","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10255","key":"10.1016\/j.jiph.2020.12.023_bib0505","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"10249","key":"10.1016\/j.jiph.2020.12.023_bib0510","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.12.023_bib0515","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","author":"Walsh","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120307796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120307796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:08:37Z","timestamp":1761750517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034120307796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1876034120307796"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2020.12.023","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk management strategies and therapeutic modalities to tackle COVID-19\/SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2020.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}